2004
DOI: 10.1182/blood.v104.11.4911.4911
|View full text |Cite
|
Sign up to set email alerts
|

Preliminary Report of Risk-Based Approach in Korean Patients with Newly Diagnosed Multiple Myeloma.

Abstract: Purpose: The purpose of this study was to examine the impact of different approaches stratified on risk based on chromosome 13 deletion and serum beta-2 microglobulin (MG) level would lead to survival benefit in patients with newly-diagnosed multiple myeloma. Patients and Methods: At diagnosis, fresh marrow samples for FISH and serum for beta-2 MG were sent to central laboratory and reviewed. Patients who had chromosome 13 deletion and high beta-2 MG (>2.5 mg/L) were considered to have hi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2006
2006
2016
2016

Publication Types

Select...
3

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…They began to conduct small multicenter studies, initially as a retrospective analysis testing the feasibility of ASCT [ 74 ], followed by a prospective trial [ 75 ]. A more sophisticated prospective trial of risk-adapted therapy based on FISH and serum β2-microglobulin results, in which allogeneic transplantation is included for the high-risk group, was attempted [ 76 ]. Later, the efficacies of bortezomib [ 77 ] or thalidomide [ 78 ] in patients with R/R MM were evaluated retrospectively in small numbers of patients, with the advent of novel agents in Korea.…”
Section: Korean Studies On Multiple Myelomamentioning
confidence: 99%
“…They began to conduct small multicenter studies, initially as a retrospective analysis testing the feasibility of ASCT [ 74 ], followed by a prospective trial [ 75 ]. A more sophisticated prospective trial of risk-adapted therapy based on FISH and serum β2-microglobulin results, in which allogeneic transplantation is included for the high-risk group, was attempted [ 76 ]. Later, the efficacies of bortezomib [ 77 ] or thalidomide [ 78 ] in patients with R/R MM were evaluated retrospectively in small numbers of patients, with the advent of novel agents in Korea.…”
Section: Korean Studies On Multiple Myelomamentioning
confidence: 99%